← Back to Home

Selectively Clearing IgG4 Antibodies: GlycoEra’s GE8820 Begins Human Trials

GE8820 is being developed to remove potentially disease-causing antibodies while preserving other immune defenses. This strategy has entered testing in healthy adults, but whether it can safely lower IgG4 and, in turn, improve autoimmune diseases still requires evaluation in stages.

By SURL BioNews

Antibodies protect the body, but they can also become a source of harm in certain autoimmune diseases. GE8820 is being developed to address how to remove a disease-associated subset while preserving the protective effects of other antibodies. On November 16, GlycoEra announced that dosing had begun in healthy volunteers, bringing this strategy for selectively clearing IgG4 antibodies into human testing.

GE8820 is an extracellular protein degrader. According to the company, it uses the body’s liver-mediated clearance system to remove IgG4 and is designed to preserve other protective immunoglobulins. The company says it is the first IgG4-selective extracellular degrader to enter clinical development; however, no trial results are currently available to assess whether both selectivity and safety can be achieved in humans.

The Australian New Zealand Clinical Trials Registry record provides additional details on the study design. This Phase 1 trial, sponsored by GlycoEra AG and registered as ACTRN12626001214325, plans to recruit 60 healthy adults aged 18 to 64 in Queensland, Australia, to evaluate intravenous infusion and subcutaneous injection using a randomized, placebo-controlled design. The single ascending dose portion initially plans five intravenous dosing cohorts and one subcutaneous dosing cohort, each initially allocated four participants receiving GE8820 and two receiving placebo. A multiple ascending dose evaluation is also planned.

The study will first assess adverse events following dosing, along with changes in vital signs, electrocardiograms, and laboratory tests; blood drug concentrations and the extent of IgG4 reduction are secondary assessments. The registry record was last updated on October 1, when it still listed recruitment as not yet started. That update preceded the dosing announcement, so this field cannot be used to conclude that the study has still not begun.

The evidence supporting this exploration in humans still comes mainly from preclinical research. GlycoEra says that in nonhuman primate studies, a single intravenous dose reduced circulating human IgG4 by more than 95%, with the maximum reduction reached in less than one day. These are company-reported animal study results and cannot be directly interpreted as effects in humans; even a substantial reduction in IgG4 in healthy participants would not yet be sufficient to demonstrate that patients’ diseases would improve as a result.

The company expects to release Phase 1a data in the first half of 2027 to support subsequent Phase 1b trials in patients with pemphigus vulgaris and primary membranous nephropathy. The immediate priority is to identify doses and levels of antibody clearance that humans can tolerate; whether this clearance can safely translate into sustained improvements in symptoms or organ function will require answers from patient trials.

References

  1. GlycoEra / PR Newswire
  2. GlycoEra
  3. Australian New Zealand Clinical Trials Registry (ANZCTR)